Investigations Neutrophil/ 1.581 (0.84,2.88) 2.48 (1.46,4.76) 1.23(0.76,2.19) 0.001 NA lymphocyte (-3.42) 278 (213,356) 292 (179,356) 278(227,356) 0.506 NA Platelet (-0.67) 1.75 (0.98,4.98) 2.14 (0.88,4.57) 1.65(1.00,5.12) 0.920 NA C-reactive protein (-0.13) 28 (25,32) 26 (23,29) 31 (29,33) 0.015 NA Albumin (-2.43) 39 (24,84) 40 (25,82) 38 (23,113) 0.990 NA ALT2 (-0.13) 5.94 (1.78,19.80) Adenovirus type 0.002 (n=79) Type 7 43 (54.4) 19 (82.6) 24 (44.4) Non-7 types 36 (45.6) 4 (17.4) 30 (55.6) Treatment PICU3 admission 14 (15.2) 13 (52.0) 1 (1.5) <0.001 71.5 (8.54,598.62) Ventilation4 47 (51.2) 21 (84.0) 26 (38.9) <0.001 8.28 (2.55, 26.86) Steroids 13 (14.1) 12 (48.0) 1 (1.5) <0.001 11.49 (3.44, 38.10) Duration of NA hospitalization, days, 4.5 (1.6-07.40) 10.0 (4.0-22.50) 4.0 (3.0-6.0) < 0.001 median (IQR) (-3.83) *Fishers exact test 1IQR: interquartile range; 2ALT: alanine transferase; 3PICU: Paediatric Intensive Care Unit; 4invasive or non-invasive ventilation Table 6: Multivariate analysis of risk factors associated with respiratory complications post-adenovirus pneumonia
Investigations Neutrophil/ lymphocyte Platelet C-reactive protein Albumin ALT2 1.581 (0.84,2.88) 278 (213,356) 1.75 (0.98,4.98) 28 (25,32) 39 (24,84) 2.48 (1.46,4.76) 292 (179,356) 2.14 (0.88,4.57) 26 (23,29) 40 (25,82) 1.23(0.76,2.19) 278(227,356) 1.65(1.00,5.12) 31 (29,33) 38 (23,113) 0.001 (-3.42) 0.506 (-0.67) 0.920 (-0.13) 0.015 (-2.43) 0.990 (-0.13) NA NA NA NA NA Adenovirus type (n=79) Type 7 Non-7 types 43 (54.4) 36 (45.6) 19 (82.6) 4 (17.4) 24 (44.4) 30 (55.6) 0.002 5.94 (1.78,19.80) Treatment PICU3 admission Ventilation4 Steroids 14 (15.2) 47 (51.2) 13 (14.1) 13 (52.0) 21 (84.0) 12 (48.0) 1 (1.5) 26 (38.9) 1 (1.5) <0.001 <0.001 <0.001 71.5 (8.54,598.62) 8.28 (2.55, 26.86) 11.49 (3.44, 38.10) Duration of hospitalization, days, median (IQR) 4.5 (1.6-07.40) 10.0 (4.0-22.50) 4.0 (3.0-6.0) < 0.001 (-3.83) NA *Fishers exact test 1IQR: interquartile range; 2ALT: alanine transferase; 3PICU: Paediatric Intensive Care Unit; 4invasive or non-invasive ventilation Table 6: Multivariate analysis of risk factors associated with respiratory complications post-adenovirus pneumonia